Dr Helen Bright FRSM, Chief Scientific Officer, Centauri Therapeutics discusses the intricacies of the body’s natural immune defences and explores how cutting-edge research is seeking to exploit it in order to drive development of a broad spectrum of innovative new immunotherapeutic technologies. The body's natural immune defences, whether in response… Read More
Daiichi Sankyo and German research institute BioMed X have agreed a new partnership to advance the development of bi- and multi-specific biologics for treating solid tumours. The new project, entitled ‘New Strategies for Targeting of Solid Tumours with Multi-Specific Biologics (MTT; Multi-Specific Targeting of Tumours)’, will be hosted at the… Read More
Tecvayli (teclistamab) has been recommended for relapsed and refractory multiple myeloma (RRMM) in England and Wales, leading analysts to predict Johnson & Johnson (J&J) will dominate the bispecific T-cell engagers (BiTEs) market by 2030. The UK National Institute for Health and Care Excellence (NICE) recommended teclistamab… Read More
A new Case Study is now available to download for free: ‘In Vivo Evaluation Of Bispecific-Cell Engager Efficacy & Safety‘. Discover a clinically predictive and reproducible platform developed by The Jackson Laboratory for simultaneous efficacy and safety assessment. This platform identifies patient-therapy combinations at risk of developing… Read More
Discover a clinically predictive and reproducible platform developed by The Jackson Laboratory for simultaneous efficacy and safety assessment. This platform identifies patient-therapy combinations at risk of developing severe inflammatory syndrome, a potentially fatal complication. Optimise the safety profiles of your immunomodulatory therapeutics before first-in-human trials by leveraging this platform. In… Read More
Moderna and Immatics have announced a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high, unmet medical need. This broad multi-platform collaboration will leverage the scientific expertise and core operational capabilities of both companies, combining Immatics’ TCR platform with Moderna’s… Read More
From June 20-22, 2023, Cambridge Healthtech Institute hosted the seventh annual Immuno-Oncology Summit Europe in London. DDW’s Megan Thomas shares highlights from the event programmes. Programmes This year’s summit was made up of conference programmes, which included: Modulating the Tumour Microenvironment; Next-Generation Cell-Based Immunotherapies; Bispecific and Multi-Specific Antibody Therapeutics, and… Read More
Discover the groundbreaking findings from a study on bispecific T cell engagers conducted by The Jackson Laboratory. This case study delves into the tools available for assessing cytokine release and tumour growth inhibition. Explore the implications of donor-specific responses and how this knowledge can optimise the development of immunomodulatory therapeutics. Read More
Discover the groundbreaking findings from a study on bispecific T-cell engagers conducted by The Jackson Laboratory. This case study delves into the tools available for assessing cytokine release and tumour growth inhibition. Explore the implications of donor-specific responses and how this knowledge can optimise the development of immunomodulatory therapeutics. What… Read More
Dr Michael Fiebig, Chief Scientific Officer, Absolute Antibody offers insight for those starting with a new bispecific antibody project who may feel a little daunted by the wealth of formats out there. Over the past 10-plus years, there has been a dramatic rise in the exploitation of bispecific antibodies with… Read More
Recent biotechnological advances have fuelled development bispecific antibodies (bsAbs) in the last 10 years. However, the functional analysis of bsAbs during bioprocessing adds a challenge for scientists given the array of bsAbs populated by many different species, comprising many different formats, and that traditional SPR and ELISA methods for bsAbs… Read More
